// COMPANY
Disco Pharmaceuticals
SECTOR BIOTECHMENTIONS 2LAST SEEN NOVEMBER 19, 2026
Discussed in
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
m_and_a·Axios Pro Rata·NOVEMBER 19, 2026
“signing a strategic collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) that includes $40m upfront and up to $2.5b in earnouts.”
Source→02
m_and_a·Axios Pro Rata·NOVEMBER 19, 2026
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.